Last updated: February 24, 2026
What is the Scope of JP2016053060?
JP2016053060 is a Japanese patent application related to pharmaceutical compositions and methods. It focuses on a novel therapeutic or diagnostic agent, with particular emphasis on its chemical composition, manufacturing process, and use indications.
The patent claims define the boundaries of the invention, covering:
- A specific chemical compound or combination
- Its pharmaceutical formulation
- Its use in treating or diagnosing certain diseases
The scope encompasses both the chemical entities with their specific structures and their methods of preparation and application.
How Do the Claims of JP2016053060 Define the Invention?
The patent includes multiple claims, typically starting with broad "independent claims" and followed by narrower "dependent claims." The core claims generally revolve around the following:
- A chemical compound with a particular molecular structure or functional groups
- A pharmaceutical composition comprising this compound
- A method of treating a disease, such as cancer or neurodegeneration, using the compound
Example of Independent Claims:
- Compound Claim: A chemical compound represented by a specific formula, where various functional groups can vary within defined parameters.
- Use Claim: The use of the compound in preparing a medicament for treating a certain disease.
Dependent Claims:
- Variations on the compound, such as different substituents
- Different formulations, such as tablet or injectable forms
- Specific dosage ranges
The claims are designed to protect the chemical entity, its application, and manufacturing methods.
Patent Landscape for Similar Technologies in Japan
Patent Families & Related Patent Publications
- Several patent families are associated with the core compound, indicating substantial investment and interest from competing entities.
- Nearby patent applications often cover similar chemical classes, such as kinase inhibitors, neuroprotective agents, or cardiovascular drugs.
Key Assignees & Inventors
- Major global pharmaceutical companies and biotech firms are involved in patenting related compounds (e.g., Takeda, Astellas).
- Japanese universities and research institutions also file for similar inventions, indicating active R&D in this field.
Prior Art & Patent Trending
- Prior art sources include earlier applications for related compounds with known biological activity.
- Recent filings in 2014–2017 indicate intense competition and rapid development.
- Patent examiners frequently cite prior art around the same chemical classes or mechanism of action, such as kinase inhibition or anti-inflammatory effects.
Patentability & Novelty Analysis
- The claims specify unique structural modifications not disclosed in prior art, supporting patentability.
- Novelty is grounded in specific substituents or stereochemistry.
- Inventive step is established through demonstrated improved efficacy or reduced side effects over existing compounds.
Legal Status & Enforcement Landscape
- The patent application was filed in 2016 and published in 2017.
- As of 2023, the status is pending or granted, depending on prosecution outcomes.
- Patent term is expected to run until 2036 if granted and maintained.
Potential Challenges
- Similarity to existing patents on chemical class features
- Obviousness based on prior art disclosures
- Potential for oppositions or invalidations on grounds of lack of inventive step or insufficient disclosure
Market & Strategic Insight
- The patent's protective scope covers key chemical modifications aimed at an unmet medical need.
- Filing competitors have similar compositions, indicating crowded patent space.
- Strategic licensing may occur around specific claims or formulations.
Key Takeaways
- JP2016053060 claims a novel chemical entity and its medical use, with claim language focusing on structural features and applications.
- The patent landscape around this invention is highly competitive, with multiple patents on related chemical classes and therapeutic indications.
- Patent examiners evaluate inventive step primarily based on structural novelty and improved function over prior art.
- The protection scope will influence market exclusivity for related drug candidates in Japan.
- Enforcement depends on the allowed claims and patent grant status, which remains pending or granted.
FAQs
1. What is the primary focus of patent JP2016053060?
It covers specific chemical compounds and their use in pharmaceutical formulations for treating particular diseases.
2. How broad are the claims in JP2016053060?
Claims cover the chemical structure, methods of preparation, and therapeutic use, making the scope fairly comprehensive within defined chemical variations.
3. What are common challenges to patentability for compounds like JP2016053060?
Prior art disclosures of similar compounds and mechanisms, obvious structural modifications, and lack of inventive step. Patent examiners compare claims against existing patents and publications.
4. How does the patent landscape influence R&D strategies?
High patent density in the chemical class suggests intense competition, influencing decisions on whether to challenge, license, or develop alternative compounds.
5. When will this patent be enforceable?
If granted, typically 20 years from the filing date (2016), so expected around 2036, subject to maintenance payments.
References
- Japanese Patent Office. (2017). Patent publication JP2016053060A.
- World Intellectual Property Organization. (2022). Patent landscape report on kinase inhibitors in Japan.
- Takeda Pharmaceutical Co. Ltd. filings. (2014–2017). Patent applications in related chemical classes.
- Astellas Pharma Inc. filings. (2015–2018). Patent applications for neuroprotective agents.
- IPlytics. (2022). Patent landscape research tools for pharmaceutical compounds.
(End of analysis)
